The company is commercialising oncology treatment and supportive care products via its US commercial organization, Midatech Pharma US.

In Europe, it is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of cancer, endocrine disorders such as diabetes and immunotherapy for autoimmune diseases.